Concurrent anemia and elevated C-reactive protein predicts HIV clinical treatment failure, including tuberculosis, after antiretroviral therapy initiation

Rupak Shivakoti, Wei Teng Yang, Nikhil Gupte, Sima Berendes, Alberto La Rosa, Sandra W. Cardoso, Noluthando Mwelase, Cecilia Kanyama, Sandy Pillay, Wadzanai Samaneka, Cynthia Riviere, Patcharaphan Sugandhavesa, Brento Santos, Selvamuthu Poongulali, Srikanth Tripathy, Robert C. Bollinger, Judith S. Currier, Alice M. Tang, Richard D. Semba, Parul ChristianThomas B. Campbell, Amita Gupta

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Background: Anemia is a known risk factor for clinical failure following antiretroviral therapy (ART). Notably, anemia and inflammation are interrelated, and recent studies have associated elevated C-reactive protein (CRP), an inflammation marker, with adverse human immunodeficiency virus (HIV) treatment outcomes, yet their joint effect is not known. The objective of this study was to assess prevalence and risk factors of anemia in HIV infection and to determine whether anemia and elevated CRP jointly predict clinical failure post-ART. Methods: A case-cohort study (N = 470 [236 cases, 234 controls]) was nested within a multinational randomized trial of ART efficacy (Prospective Evaluation of Antiretrovirals in Resource Limited Settings [PEARLS]). Cases were incident World Health Organization stage 3, 4, or death by 96 weeks of ART treatment (clinical failure). Multivariable logistic regression was used to determine risk factors for pre-ART (baseline) anemia (females: hemoglobin <12.0 g/dL; males: hemoglobin <13.0 g/dL). Association of anemia as well as concurrent baseline anemia and inflammation (CRP ≥10 mg/L) with clinical failure were assessed using multivariable Cox models. Results: Baseline anemia prevalence was 51% with 15% prevalence of concurrent anemia and inflammation. In analysis of clinical failure, multivariate-adjusted hazard ratios were 6.41 (95% confidence interval [CI], 2.82-14.57) for concurrent anemia and inflammation, 0.77 (95% CI,. 37-1.58) for anemia without inflammation, and 0.45 (95% CI,. 11-1.80) for inflammation without anemia compared to those without anemia and inflammation. Conclusions: ART-naive, HIV-infected individuals with concurrent anemia and inflammation are at particularly high risk of failing treatment, and understanding the pathogenesis could lead to new interventions. Reducing inflammation and anemia will likely improve HIV disease outcomes. Alternatively, concurrent anemia and inflammation could represent individuals with occult opportunistic infections in need of additional screening.

Original languageEnglish (US)
Pages (from-to)102-110
Number of pages9
JournalClinical Infectious Diseases
Issue number1
StatePublished - Jul 1 2015


  • CRP
  • HIV
  • anemia
  • antiretroviral therapy
  • inflammation

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Concurrent anemia and elevated C-reactive protein predicts HIV clinical treatment failure, including tuberculosis, after antiretroviral therapy initiation'. Together they form a unique fingerprint.

Cite this